Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial to Determine the Safety of TRIMELVax for Stage IIIC and IV Melanoma Patients in Progression to Immunotherapy Treatment (Checkpoint Inhibitors)

NCT06556004 is registered in ClinicalTrials.gov with University of Chile as lead sponsor.

NCT NCT06556004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06556004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial to Determine the Safety of TRIMELVax for Stage IIIC and IV Melanoma Patients in Progression to Immunotherapy Treatment (Checkpoint Inhibitors)
Lead sponsor
University of Chile
Phase
Phase 1
Overall status
Unknown status
Start date
May 2, 2021
Completion date
March 31, 2025
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iiic, melanoma stage iv